Sitemap
- Home
- Research Team
- Frequently Asked Questions
- Donate
- Simpkins Lab
- Center for Gynecologic Cancer Immunotherapies
- Ovarian Cancer Translational Center of Excellence
- Cervical
- Cervical
-
Ovarian
- NRG-GY019 Eligibility Criteria
- CAPRI Eligibility Criteria
- TC-210 Eligibility Criteria
- STRO Eligibility Criteria
- STRO+bev Eligibility Criteria
- GOG3035 Eligibility Criteria
- CC008 Eligibility Criteria
- Penn Legacy Tissue Program Eligibility
- GOG 3049 Eligibility
- GOG 3066 Eligibility Criteria
- STAR-101 Eligibility Criteria
- NRG-GY031 Eligibility Criteria
- Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib Eligibility Criteria
- WISP II Eligibility Criteria
- Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Eligibility Criteria
- Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3) Eligibility Criteria
- GOG 3104 Eligibility Criteria
- Primary Peritoneal
- Fallopian Tube
- Uterine / Endometrial
- Solid Tumor
- Immunotherapy
- Other